back to US directory
us clinical guidance

Impetigo and ecthyma

US diagnosis, limited-versus-extensive treatment, culture strategy, transmission control and deeper-infection escalation.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Children and adults with suspected bullous or nonbullous impetigo or ecthyma. The 2014 IDSA guideline remains listed in the current IDSA directory but is older and therefore requires explicit clinical review. This page does not cover staphylococcal scalded-skin syndrome, extensive burns, necrotizing infection, immunocompromised-host syndromes or outbreak management in detail.
sources for this section:IDSA SSTI 2014

The Bottom Line

  • Recognize superficial fragile vesicles, pustules or honey-colored crusted erosions and distinguish them from herpes, contact dermatitis, tinea, scabies, inflammatory disease and deeper ulceration.
  • Culture pus or exudate when organism identification will guide care, while acknowledging that a typical limited presentation may be treated without microbiology under IDSA guidance.
  • Use topical therapy for limited uncomplicated impetigo and systemic therapy for numerous lesions, ecthyma or an outbreak where reducing transmission is important; choose an agent active against likely staphylococci and streptococci.
  • Consider methicillin-resistant Staphylococcus aureus only when epidemiology, previous culture, treatment failure or local prevalence supports it rather than using broad MRSA treatment for every crusted lesion.
sources for this section:IDSA SSTI 2014

Practical clinical workflow

1
Document lesion onset, distribution, pain, itch, blistering, household or team spread, trauma, eczema, animal exposure, previous MRSA and systemic symptoms; examine for abscess or cellulitis.
2
Estimate lesion number and surface area, identify bullous disease or deeper ecthyma, and obtain culture from an appropriate lesion when disease is extensive, recurrent, outbreak-associated or failing treatment.
3
Select topical or oral treatment, review allergy and current labeling, explain gentle cleansing and avoidance of shared towels or equipment, and address underlying dermatitis or skin trauma.
4
Reassess spread or nonresponse for resistance, incorrect application, poor adherence, abscess requiring drainage, herpes infection, fungal disease or an inflammatory mimic.
sources for this section:IDSA SSTI 2014

Safety boundaries and escalation

  • Fever, rapidly spreading erythema, disproportionate pain, hypotension, extensive blistering, mucosal involvement or skin tenderness requires urgent assessment for invasive infection or a severe blistering disorder.
  • Periorbital involvement, an immunocompromised host, a very young infant or widespread bullous disease warrants a lower threshold for specialist or hospital evaluation.
  • Do not use topical antibiotics indefinitely or repeatedly without reassessment; local reactions and antimicrobial resistance can obscure treatment failure.
  • Clusters in childcare, schools, contact sports or households may require facility and local public-health infection-control advice beyond individual treatment.
sources for this section:IDSA SSTI 2014

Localization

Use local US S. aureus susceptibility and outbreak policy.
sources for this section:IDSA SSTI 2014

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Infectious Diseases Society of AmericaPractice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 UpdateDOI 10.1093/cid/ciu296; correction DOI 10.1093/cid/civ114 路 published 2014-07-15 路 updated 2015-05-01 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.